Tempus AI (NASDAQ:TEM) Now Covered by Mizuho

Mizuho began coverage on shares of Tempus AI (NASDAQ:TEM) in a research note released on Thursday, MarketBeat.com reports. The firm issued an outperform rating and a $100.00 price objective on the stock.

A number of other equities analysts also recently weighed in on TEM. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Robert W. Baird assumed coverage on Tempus AI in a research report on Tuesday. They set an “outperform” rating and a $59.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Needham & Company LLC raised their price target on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, HC Wainwright cut their target price on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tempus AI presently has an average rating of “Hold” and an average target price of $85.92.

Tempus AI Trading Down 1.1%

NASDAQ TEM traded down $0.65 during trading on Thursday, reaching $59.31. 4,461,226 shares of the stock traded hands, compared to its average volume of 5,633,564. The stock’s 50-day moving average price is $62.60 and its 200 day moving average price is $73.38. The firm has a market cap of $10.55 billion, a price-to-earnings ratio of -49.85 and a beta of 5.22. Tempus AI has a fifty-two week low of $36.22 and a fifty-two week high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Insider Buying and Selling

In other news, CFO James William Rogers sold 19,966 shares of Tempus AI stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the transaction, the chief financial officer owned 111,250 shares in the company, valued at $8,143,500. This trade represents a 15.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Andrew Polovin sold 12,874 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $75.00, for a total value of $965,550.00. Following the completion of the transaction, the executive vice president owned 107,590 shares in the company, valued at $8,069,250. The trade was a 10.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 544,188 shares of company stock valued at $37,163,496 in the last 90 days. 26.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Tempus AI

A number of large investors have recently bought and sold shares of the business. Cranbrook Wealth Management LLC purchased a new stake in shares of Tempus AI in the third quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new stake in Tempus AI in the third quarter valued at approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in Tempus AI during the 4th quarter worth about $27,000. GAMMA Investing LLC acquired a new position in shares of Tempus AI in the 3rd quarter valued at $28,000. Finally, Allworth Financial LP boosted its position in shares of Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.